Heart Diseases
Heart Diseases
Search
Early careers
At Boehringer Ingelheim, we know how important it is to lay the right foundations in your career and build on them with care and support.
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction
JARDIANCE® is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for chronic heart failure1 Heart failure represents a significant, growing disease burden
New data presented at the American Thoracic Society Conference showed nintedanib slows loss of pulmonary function in people living with systemic sclerosis associated ILD
New data presented at the American Thoracic Society Conference showed nintedanib slows loss of pulmonary function in people living with systemic sclerosis associated ILD
Meet our Team
Find all our contact information here as well as information on where you can meet us virtually or in person. You can also find out how to submit your opportunity to our BD&L team
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Sustainable Development - Our Commitment
Our Commitment
New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype
New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype
Treatment options for parasite control in cattle
Treatment options for parasite control in cattle
Ontario’s Dr. Trevor DeVries named 2021 Metacam® 20 Bovine Welfare Award winner
Ontario’s Dr. Trevor DeVries named 2021 Metacam® 20 Bovine Welfare Award winner
Retinal Diseases
Retinal Diseases
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Parasiticides
Science and Innovation - Animal Health Innovation - Parasiticides
Effective management practices for parasite control in cattle
Effective management practices for parasite control in cattle
Spark Innovation Challenge
The Type 2 Spark Innovation Challenge encourages innovation, collaboration and change in approaches to addressing T2D in British Columbia. Continue reading.
Working at Boehringer Ingelheim
Working at Boehringer Ingelheim
Monophasic Salmonella Calls for a Comprehensive Vaccination Strategy
Monophasic Salmonella Calls for a Comprehensive Vaccination Strategy
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis
Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer
Boehringer Ingelheim Canada supports PF Awareness Month with Life with PF campaign
Boehringer Ingelheim Canada supports PF Awareness Month with Life with PF campaign
Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD
OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.
Simon Manyara
Simon Manyara works with our culture and sustainability team towards making a positive social impact and creating a sustainable future.
Alberta’s Dr. Calvin Booker named bovine veterinarian of the year by the Western Canadian Association of Bovine Practitioners
Alberta’s Dr. Calvin Booker named bovine veterinarian of the year by the Western Canadian Association of Bovine Practitioners